WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Performance Score
Market Cap
Revenue
EBITDA
Earnings
EPS
Revenue Growth Y/Y
Revenue Growth 5Y
Earnings Growth Y/Y
Earnings Growth 5Y
Earnings Date
FONR
FONAR CORP
$112.91M$102.42M$25.75M$12.16M$1.895.78%4.06%51.20%-8.83%2024-05-13
IDXX
IDEXX LABORATORIES INC
$39.70B$3.66B$1.22B$845.04M$10.178.72%10.59%25.25%18.57%2024-05-01
ICLR
ICON PLC
$24.07B$8.12B$1.55B$612.34M$7.464.89%25.62%20.32%4.59%2024-04-25
STRR
STAR EQUITY HOLDINGS INC
$13.49M$45.79M$26.87M$23.22M$1.61-19.88%-15.16%N/A34.19%2024-05-13
RVTY
REVVITY INC
$12.28B$2.75B$1.25B$693.09M$5.56-16.95%-0.20%23.28%20.93%2024-04-29
A
AGILENT TECHNOLOGIES INC
$38.81B$6.74B$1.69B$1.24B$4.22-2.81%6.19%-5.17%3.46%2024-05-21
MEDP
MEDPACE HOLDINGS INC
$11.51B$1.89B$382.14M$282.81M$9.2029.17%21.76%21.53%35.02%2024-04-23
NEOG
NEOGEN CORP
$2.58B$929.24M$188.76M$1.57M$0.0228.93%17.63%-50.00%-49.27%
TMO
THERMO FISHER SCIENTIFIC INC
$206.49B$42.86B$11.06B$6.00B$15.52-4.58%11.96%-12.56%16.25%2024-04-24
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$11.68B$4.13B$1.03B$474.62M$9.273.86%12.75%-3.13%14.45%2024-05-09
QGEN
QIAGEN NV
$9.01B$1.97B$688.56M$341.30M$1.50-8.23%5.53%-19.35%11.61%2024-04-30
SHC
SOTERA HEALTH CO
$3.08B$1.05B$406.83M$51.38M$0.184.54%7.06%N/AN/A2024-05-02
ENZ
ENZO BIOCHEM INC
$57.89M$12.81M$33.74M$32.57M$0.67N/A-32.08%N/AN/A2024-06-12
LH
LABORATORY CORP OF AMERICA HOLDINGS
$16.77B$12.16B$1.55B$418.00M$4.802.51%1.42%-65.84%-11.23%2024-04-25
DHR
DANAHER CORP
$174.84B$23.89B$8.04B$4.74B$6.44-10.33%6.98%-34.29%11.24%2024-04-23
CSTL
CASTLE BIOSCIENCES INC
$527.04M$219.79M-$45.02M-$57.47M-$2.1460.38%57.35%N/AN/A2024-05-01
TWST
TWIST BIOSCIENCE CORP
$1.64B$262.36M-$169.85M-$205.80M-$3.6121.58%51.75%N/AN/A2024-05-03
DGX
QUEST DIAGNOSTICS INC
$13.94B$9.25B$1.69B$854.00M$7.59-6.38%4.20%-6.30%7.09%2024-04-23
MTD
METTLER TOLEDO INTERNATIONAL INC
$25.61B$3.79B$1.17B$788.78M$36.10-3.35%5.23%-6.93%12.17%2024-05-10
XGN
EXAGEN INC
$24.63M$52.55M-$18.21M-$23.69M-$1.3415.33%10.13%N/AN/A2024-05-13
WAT
WATERS CORP
$17.42B$2.96B$1.00B$642.23M$10.87-0.52%4.09%-7.88%7.11%2024-05-07
ACRS
ACLARIS THERAPEUTICS INC
$87.24M$31.25M-$87.99M-$88.48M-$1.275.03%38.41%N/AN/A2024-05-06
SERA
SERA PROGNOSTICS INC
$317.45M$306.00k-$34.76M-$36.24M-$1.1614.18%N/AN/AN/A2024-05-08
IQV
IQVIA HOLDINGS INC
$41.23B$14.98B$3.26B$1.36B$7.393.98%7.55%26.98%42.22%2024-04-25
PRPO
PRECIPIO INC
$9.59M$15.20M-$4.32M-$5.85M-$4.5161.46%39.62%N/AN/A2024-05-15
PSNL
PERSONALIS INC
$61.11M$73.48M-$94.95M-$108.30M-$2.2512.97%14.23%N/AN/A2024-05-01
EXAS
EXACT SCIENCES CORP
$11.52B$2.50B$52.20M-$204.15M-$1.1319.93%40.63%N/AN/A2024-05-07
NTRA
NATERA INC
$10.54B$1.08B-$383.28M-$434.80M-$3.7831.99%33.26%N/AN/A2024-05-07
OLK
OLINK HOLDING AB (PUBL)
$2.77B$169.60M-$20.05M-$31.60M-$0.2521.27%N/AN/AN/A2024-05-09
DRIO
DARIOHEALTH CORP
$33.86M$20.35M-$54.38M-$63.51M-$1.93-26.41%22.45%N/AN/A2024-05-09
FLGT
FULGENT GENETICS INC
$598.97M$289.21M-$134.12M-$167.83M-$5.63-53.27%68.41%N/AN/A2024-05-03
GH
GUARDANT HEALTH INC
$2.03B$563.95M-$433.31M-$479.45M-$4.2825.45%44.14%N/AN/A2024-05-07
STIM
NEURONETICS INC
$113.97M$71.35M-$22.76M-$30.19M-$1.059.42%6.22%N/AN/A2024-05-07
DMTK
DERMTECH INC
$20.46M$15.30M-$95.04M-$100.89M-$3.095.36%44.33%N/AN/A2024-05-02
NEO
NEOGENOMICS INC
$1.76B$591.64M-$8.37M-$87.97M-$0.7016.07%16.41%N/AN/A2024-05-06
BNR
BURNING ROCK BIOTECH LTD
$81.92M$74.64MN/A-$90.79M-$0.89-6.20%20.19%N/AN/A2024-05-28
OCX
ONCOCYTE CORP
$21.18M$1.50M-$26.05M-$28.72M-$3.7556.89%N/AN/AN/A2024-05-09
RDNT
RADNET INC
$3.26B$1.62B$265.49M$3.04M$0.0513.05%10.64%-73.68%-40.49%2024-05-07
BGLC
BIONEXUS GENE LAB CORP
$15.00M$9.77M-$2.49M-$2.63M-$0.18-10.60%115.07%N/AN/A
PRE
PRENETICS GLOBAL LTD
$38.65M$21.74MN/A-$62.72M-$5.5865.17%18.68%N/AN/A
APDN
APPLIED DNA SCIENCES INC
$5.74M$9.00M-$5.89M-$7.29M-$0.55-53.31%16.79%N/AN/A2024-05-09
LAB
STANDARD BIOTOOLS INC
$736.90M$106.34M-$65.66M-$74.66M-$0.948.57%-1.20%N/AN/A2024-05-07
XWEL
XWELL INC
$5.86M$30.11M-$24.16M-$27.74M-$6.64-46.18%-9.68%N/AN/A2024-05-13
MDXH
MDXHEALTH SA
$6.20M$70.19M-$20.47M-$43.10M-$16.6089.43%N/AN/AN/A2024-05-08
CDNA
CAREDX INC
$417.85M$280.32M-$182.19M-$190.28M-$3.54-12.89%29.63%N/AN/A2024-05-08
BDSX
BIODESIX INC
$121.18M$49.09M-$37.10M-$52.15M-$0.6428.46%19.16%N/AN/A2024-05-09
ME
23ANDME HOLDING CO
$243.87M$247.99M-$490.64M-$521.97M-$1.11-19.40%N/AN/AN/A2024-05-26
NDRA
ENDRA LIFE SCIENCES INC
$2.57M$0.00-$9.78M-$10.06M-$1.58N/A-100.00%N/AN/A2024-05-13
CHEK
CHECK-CAP LTD
$13.22M$0.00-$19.08M-$17.62M-$3.02N/AN/AN/AN/A2024-05-06
ULS
UL SOLUTIONS INC
N/A$2.68B$519.00M$260.00M$1.306.27%N/A-11.56%N/A
PRPH
PROPHASE LABS INC
$98.17M$44.38M-$14.83M-$16.78M-$0.98-63.81%27.59%N/AN/A2024-05-09
NOTV
INOTIV INC
$121.22M$585.17M$59.57M-$33.21M-$1.30-0.18%81.64%N/AN/A2024-05-09
AWH
ASPIRA WOMEN's HEALTH INC
$43.57M$9.15M-$16.50M-$16.69M-$1.8111.85%24.56%N/AN/A2024-05-09
OPK
OPKO HEALTH INC
$857.30M$863.50M-$65.62M-$188.86M-$0.25-14.01%-2.70%N/AN/A2024-05-01
VNRX
VOLITIONRX LTD
$50.64M$775.30k-$33.68M-$35.32M-$0.50153.04%N/AN/AN/A2024-05-08
GENE
GENETIC TECHNOLOGIES LTD
$563.24k$5.55MN/A-$8.33M-$2.98-3.27%136.93%N/AN/A
MYGN
MYRIAD GENETICS INC
$1.66B$753.20M-$186.10M-$263.30M-$3.1811.03%-1.10%N/AN/A2024-05-01
ISPC
ISPECIMEN INC
$3.83M$9.93M-$9.02M-$11.10M-$1.23-4.56%N/AN/AN/A2024-05-02
BIAF
BIOAFFINITY TECHNOLOGIES INC
$32.13M$2.53M-$7.63M-$7.94M-$0.9152,627.44%N/AN/AN/A2024-05-13
ILMN
ILLUMINA INC
$18.54B$4.50B-$608.00M-$1.16B-$7.34-1.75%6.21%N/AN/A2024-05-02
PMD
PSYCHEMEDICS CORP
$14.70M$22.10M-$768.00k-$4.15M-$0.72-12.45%-12.33%N/AN/A2024-05-07
MYNZ
MAINZ BIOMED NV
$19.13M$895.48k-$24.62M-$26.30M-$1.6269.00%N/AN/AN/A2024-05-13
TRIB
TRINITY BIOTECH PLC
$14.41M$56.83MN/A-$24.02MN/A-9.10%-10.15%N/AN/A
MMA
ALTA GLOBAL GROUP LTD
N/A$1.54M-$16.12M-$20.60M-$5.2663.35%N/AN/AN/A
CNTG
CENTOGENE NV
$12.72M$55.12M-$44.39M-$61.44M-$1.58N/AN/AN/AN/A2024-05-29
TTOO
T2 BIOSYSTEMS INC
$16.48M$7.19M-$42.53M-$50.08M-$19.19-67.75%-7.29%N/AN/A2024-05-21

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 19 points higher than the diagnostic & research industry average of 28. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 7.65% over the past year, overperforming other diagnostic & research stocks by 17 percentage points.

2. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the second best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 37.06% over the past year, overperforming other diagnostic & research stocks by 47 percentage points.

Icon has an average 1 year price target of $346.43, an upside of 18.71% from Icon's current stock price of $291.82.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Icon, 71.43% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Idexx Laboratories (NASDAQ:IDXX)


Idexx Laboratories (NASDAQ:IDXX) is the third best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock lose -0.9% over the past year, overperforming other diagnostic & research stocks by 9 percentage points.

Idexx Laboratories has an average 1 year price target of $584.00, an upside of 22.23% from Idexx Laboratories's current stock price of $477.79.

Idexx Laboratories stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Idexx Laboratories, 60% have issued a Strong Buy rating, 0% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 3.24%, which is 2 percentage points higher than the diagnostic & research industry average of 1.43%.

Qiagen Nv's dividend payout ratio of 85.3% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.29%, which is 1 percentage points higher than the diagnostic & research industry average of 1.43%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 37.4% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)


Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.44%, which is the same as the diagnostic & research industry average of 1.43%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 60% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.91% in the last day, and down -7.32% over the last week. Genetic Technologies was the among the top losers in the diagnostics & research industry, dropping -22.78% yesterday.

Genetic Technologies shares trading lower after the company announced a $2 million registered direct offering.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 6.38% in the past year. It has overperformed other stocks in the diagnostic & research industry by 16 percentage points.

2. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -53.69% in the past year. It has underperformed other stocks in the diagnostic & research industry by -44 percentage points.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 7.65% in the past year. It has overperformed other stocks in the diagnostic & research industry by 17 percentage points.

Are diagnostic & research stocks a good buy now?

46.81% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 13.68% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 36.3x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.